These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

580 related items for PubMed ID: 21193250

  • 21. Natalizumab: targeting alpha4-integrins in multiple sclerosis.
    Engelhardt B, Kappos L.
    Neurodegener Dis; 2008; 5(1):16-22. PubMed ID: 18075270
    [Abstract] [Full Text] [Related]

  • 22. Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study).
    Clerico M, Schiavetti I, De Mercanti SF, Piazza F, Gned D, Brescia Morra V, Lanzillo R, Ghezzi A, Bianchi A, Salemi G, Realmuto S, Sola P, Vitetta F, Cavalla P, Paolicelli D, Trojano M, Sormani MP, Durelli L.
    JAMA Neurol; 2014 Aug; 71(8):954-60. PubMed ID: 24977406
    [Abstract] [Full Text] [Related]

  • 23. Natalizumab therapy for multiple sclerosis.
    Derfuss T, Kuhle J, Lindberg R, Kappos L.
    Semin Neurol; 2013 Feb; 33(1):26-36. PubMed ID: 23709210
    [Abstract] [Full Text] [Related]

  • 24. The role of natalizumab in the treatment of multiple sclerosis.
    Coyle PK.
    Am J Manag Care; 2010 Jun; 16(6 Suppl):S164-70. PubMed ID: 20615052
    [Abstract] [Full Text] [Related]

  • 25. Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis.
    Planas R, Jelčić I, Schippling S, Martin R, Sospedra M.
    Eur J Immunol; 2012 Mar; 42(3):790-8. PubMed ID: 22144343
    [Abstract] [Full Text] [Related]

  • 26. Natalizumab: bench to bedside and beyond.
    Rudick R, Polman C, Clifford D, Miller D, Steinman L.
    JAMA Neurol; 2013 Feb; 70(2):172-82. PubMed ID: 23128399
    [Abstract] [Full Text] [Related]

  • 27. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.
    Calabresi PA, Giovannoni G, Confavreux C, Galetta SL, Havrdova E, Hutchinson M, Kappos L, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Lublin FD, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, AFFIRM and SENTINEL Investigators.
    Neurology; 2007 Oct 02; 69(14):1391-403. PubMed ID: 17761550
    [Abstract] [Full Text] [Related]

  • 28. Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.
    Campbell JD, McQueen RB, Miravalle A, Corboy JR, Vollmer TL, Nair K.
    Am J Manag Care; 2013 Apr 02; 19(4):278-85. PubMed ID: 23725360
    [Abstract] [Full Text] [Related]

  • 29. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis.
    O'Connor PW, Goodman A, Kappos L, Lublin FD, Miller DH, Polman C, Rudick RA, Aschenbach W, Lucas N.
    Neurology; 2011 May 31; 76(22):1858-65. PubMed ID: 21543733
    [Abstract] [Full Text] [Related]

  • 30. CD49d expression as a promising biomarker to monitor natalizumab efficacy.
    Defer G, Mariotte D, Derache N, Toutirais O, Legros H, Cauquelin B, Le Mauff B.
    J Neurol Sci; 2012 Mar 15; 314(1-2):138-42. PubMed ID: 22050952
    [Abstract] [Full Text] [Related]

  • 31. Deaths and disability from natalizumab are no longer tolerable: Yes.
    Duquette P.
    Mult Scler; 2012 Aug 15; 18(8):1068-9. PubMed ID: 22807470
    [No Abstract] [Full Text] [Related]

  • 32. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study.
    Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, O'Connor PW, Giovannoni G, Phillips JT, Lublin FD, Pace A, Kim R, Hyde R.
    Lancet Neurol; 2009 Mar 15; 8(3):254-60. PubMed ID: 19201654
    [Abstract] [Full Text] [Related]

  • 33. Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring.
    Hunt D, Giovannoni G.
    Pract Neurol; 2012 Feb 15; 12(1):25-35. PubMed ID: 22258169
    [Abstract] [Full Text] [Related]

  • 34. Deaths and disability from natalizumab are no longer tolerable: No - (they can be avoided).
    Sørensen PS.
    Mult Scler; 2012 Aug 15; 18(8):1070-2. PubMed ID: 22807471
    [No Abstract] [Full Text] [Related]

  • 35. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
    Hersh CM, Cohen JA.
    Immunotherapy; 2014 Aug 15; 6(3):249-59. PubMed ID: 24762071
    [Abstract] [Full Text] [Related]

  • 36. [Natalizumab in the treatment of multiple sclerosis].
    Horga A, Horga de la Parte JF.
    Rev Neurol; 2014 Aug 15; 45(5):293-303. PubMed ID: 17876741
    [Abstract] [Full Text] [Related]

  • 37. An update on new and emerging therapies for relapsing-remitting multiple sclerosis.
    Weinstock-Guttman B.
    Am J Manag Care; 2013 Nov 15; 19(17 Suppl):s343-54. PubMed ID: 24494635
    [Abstract] [Full Text] [Related]

  • 38. Natalizumab in relapsing-remitting multiple sclerosis.
    Outteryck O.
    Expert Rev Neurother; 2016 May 15; 16(5):471-81. PubMed ID: 27008031
    [Abstract] [Full Text] [Related]

  • 39. Progressive multifocal leukoencephalopathy and natalizumab.
    Hellwig K, Gold R.
    J Neurol; 2011 Nov 15; 258(11):1920-8. PubMed ID: 21647730
    [Abstract] [Full Text] [Related]

  • 40. Spanish consensus on the use of natalizumab (Tysabri®)-2013.
    Fernández O, García-Merino JA, Arroyo R, Álvarez-Cermeño JC, Izquierdo G, Saiz A, Olascoaga J, Rodríguez-Antigüedad A, Prieto JM, Oreja-Guevara C, Hernández MA, Moral E, Meca J, Montalbán X.
    Neurologia; 2015 Jun 15; 30(5):302-14. PubMed ID: 24360652
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.